株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

骨髄異形成症候群:世界の治験動向

Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2018

発行 GlobalData 商品コード 244194
出版日 ページ情報 英文 1258 Pages
即納可能
価格
本日の銀行送金レート: 1USD=111.09円で換算しております。
Back to Top
骨髄異形成症候群:世界の治験動向 Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2018
出版日: 2018年03月30日 ページ情報: 英文 1258 Pages
概要

当レポートでは、骨髄異形成症候群に関する臨床研究の最新動向について分析し、疾患・治療法の概要や、G7およびE7諸国における治験の状況、地域・フェーズ(相)・段階別の進行状況、有望なスポンサー、各企業・研究機関での研究の進行状況、有望な薬剤の比較といった情報を盛り込んでお届けします。

当レポートの概要

各地域における治験状況

  • 各国の治験件数と平均被験者数
    • 上位5ヶ国における治験件数; アジア太平洋地域
    • 上位5ヶ国における治験件数; 欧州
    • 主要国における治験件数; 北米
    • 上位5ヶ国における治験件数; 中東/アフリカ地域
    • 上位5ヶ国における治験件数; 中南米

G7諸国における治験件数:骨髄異形成症候群治験件数の腫瘍学治験件数に対する比率

フェーズ(相)別治験件数: G7諸国

G7諸国における治験件数:フェーズ(相)別

E7諸国における治験件数:骨髄異形成症候群治験件数の腫瘍学治験件数に対する比率

フェーズ(相)別治験件数: E7諸国

E7諸国における治験件数:フェーズ(相)別

フェーズ(相)別治験件数

  • フェーズ(相)別の進行中治験件数

進捗状況別の治験件数

評価項目別の治験件数

一定期間に採用された被験者数

スポンサーの種類別の治験件数

有望なスポンサー

治験主要参加企業 - 骨髄異形成症候群治療薬

有望な薬剤

  • 最新治験ニュース:骨髄異形成症候群

治験プロファイルの基本情報

付録

図表

目次
Product Code: GDHC4834CTIDB

GlobalData's clinical trial report, "Myelodysplastic Syndrome Global Clinical Trials Review, H1, 2018" provides an overview of Myelodysplastic Syndrome clinical trials scenario. This report provides top line data relating to the clinical trials on Myelodysplastic Syndrome. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global clinical trials landscape
  • Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
  • The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
  • The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
  • The Report provides enrollment trends for the past five years
  • Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

  • Assists in formulating key business strategies with regards to investment
  • Helps in identifying prominent locations for conducting clinical trials which saves time and cost
  • Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
  • Supports understanding of trials count and enrollment trends by country in global therapeutics market
  • Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
  • Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Table of Contents

Table of Contents

Table of Contents 2

  • List of Tables 4
  • List of Figures 5
  • Report Guidance 6
  • GlobalData Clinical Trials Report Coverage 7
  • Clinical Trials by Region 8
  • Clinical Trials and Average Enrollment by Country 9
  • Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11
  • Top Five Countries Contributing to Clinical Trials in Europe 12
  • Top Countries Contributing to Clinical Trials in North America 13
  • Top Five Countries Contributing to Clinical Trials in Middle East and Africa 14
  • Top Five Countries Contributing to Clinical Trials in Central and South America 15
  • Clinical Trials by G7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials 16
  • Clinical Trials by Phase in G7 Countries 17
  • Clinical Trials in G7 Countries by Trial Status 18
  • Clinical Trials by E7 Countries: Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials 19
  • Clinical Trials by Phase in E7 Countries 20
  • Clinical Trials in E7 Countries by Trial Status 21
  • Clinical Trials by Phase 22
  • In Progress Trials by Phase 23
  • Clinical Trials by Trial Status 24
  • Clinical Trials by End Point Status 25
  • Subjects Recruited Over a Period of Time 26
  • Clinical Trials by Sponsor Type 27
  • Prominent Sponsors 28
  • Top Companies Participating in Myelodysplastic Syndrome Therapeutics Clinical Trials 29
  • Prominent Drugs 30
  • Latest Clinical Trials News on Myelodysplastic Syndrome 31
  • Feb 20, 2018: Actinium Pharmaceuticals Announces Product Showcase and Other Visibility Extending Activities at the BMT Tandem Meetings, the Combined Annual Meetings of the Two Leading Transplant Organizations 31
  • Feb 20, 2018: Onconova Announces Presentation on Rigosertib Sodium at 2018 American Chemical Society National Meeting and Expo 31
  • Feb 20, 2018: H3 Biomedicine Preclinical Proof-of-Concept Data on First-in-Class Spliceosome-Modulator Therapy for Genomically Identified Patients with Hematological Cancers Published in Nature Medicine 32
  • Feb 08, 2018: GlycoMimetics Enters into Agreement with HOVON to Initiate Study Startup Activities for Planned Clinical Trial of GMI-1271 and Decitabine in Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Chemotherapy 32
  • Feb 05, 2018: Trethera Announces FDA Clearance of Investigational New Drug Application for TRE-515 33
  • Feb 02, 2018: Onconova Announces Presentation Of Mechanism Of Action Studies Of Rigosertib Combination With Azacitidine At American Association For Cancer Epigenetics Research Conference 33
  • Jan 29, 2018: BerGenBio: Encouraging I-O clinical data with selective AXL inhibitor bemcentinib (BGB324) supports its potential as cornerstone of cancer therapy 34
  • Jan 17, 2018: Onconova Moving Forward with Phase 3 INSPIRE Pivotal Trial with Increased Sample Size Following Promising Interim Analysis 35
  • Jan 02, 2018: Syros Announces Clinical Supply Agreement with Janssen to Evaluate SY-1425, Its First-in-Class Selective RARa Agonist, in Combination with Daratumumab in Genomically Defined AML and MDS Patients 36
  • Dec 14, 2017: Protagonist Therapeutics Announces Final Phase 1 Study Results with Novel Hepcidin Mimetic, PTG-300 36
  • Dec 11, 2017: Kura Oncology Identifies Potential Biomarkers of Activity for Lead Candidate Tipifarnib in Bone Marrow Cancers 37
  • Dec 11, 2017: New Data from Ivosidenib Phase 1 Dose-Escalation and Expansion Trial Demonstrate Durable Responses in Patients with IDH1m Relapsed or Refractory AML 37
  • Dec 11, 2017: OHSU and Aptose Present CG'806 Preclinical Data at ASH 59th Annual Meeting 38
  • Dec 11, 2017: Phase 1 Data for Flotetuzumab, MacroGenics' CD123 x CD3 DART Molecule, Presented at 59th Annual ASH Meeting 39
  • Dec 10, 2017: Acceleron Announces Updated Results from Ongoing Phase 2 Trials of Luspatercept in Myelodysplastic Syndromes at the 59th Annual Meeting of the American Society of Hematology 40
  • Dec 10, 2017: Syros Announces Initial Clinical Data from Ongoing Phase 2 Trial of SY-1425 Showing Biological and Clinical Activity as Single Agent in Genomically Defined AML and MDS Patients 40
  • Dec 09, 2017: Amphivena Presents Preclinical Data at ASH That Points to a Potentially New Treatment for MDS Patients 41
  • Clinical Trial Profile Snapshots 43

Appendix 1255

  • Abbreviations 1255
  • Definitions 1255
  • Research Methodology 1256
  • Secondary Research 1256
  • About GlobalData 1257
  • Contact Us 1257
  • Disclaimer 1257
  • Source 1258

List of Tables

List of Tables

  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Region, 2018* 8
  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2018* 11
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries, 2018* 12
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, North America, Top Countries, 2018* 13
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2018* 14
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2018* 15
  • Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2018* 16
  • Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
  • Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2018* 19
  • Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
  • Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Phase, 2018* 22
  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase 2018* 23
  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
  • Myelodysplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2018* 27
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30

List of Figures

List of Figures

  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Region (%), 2018* 8
  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2018* 9
  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2018* 10
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2018* 11
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2018* 12
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, North America, Top Countries (%), 2018* 13
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2018* 14
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2018* 15
  • Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, G7 Countries (%), 2018* 16
  • Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Phase, 2018* 17
  • Myelodysplastic Syndrome Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2018* 18
  • Proportion of Myelodysplastic Syndrome to Oncology Clinical Trials, E7 Countries (%), 2018* 19
  • Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Phase, 2018* 20
  • Myelodysplastic Syndrome Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2018* 21
  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Phase (%), 2018* 22
  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials In Progress by Phase, 2018* 23
  • Myelodysplastic Syndrome Therapeutics, Global, Clinical Trials by Trial Status, 2018* 24
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, by End Point Status, 2018* 25
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2013-2017 26
  • Myelodysplastic Syndrome Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2018* 27
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Key Sponsors, 2018* 28
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Top Companies by Phase, 2018* 29
  • Myelodysplastic Syndrome Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2018* 30
  • GlobalData Methodology 1256
Back to Top